Aprea Therapeutics, Inc. 8-K

What Happened
Aprea Therapeutics, Inc. (APRE) announced on February 18, 2026 (via a press release filed on Form 8-K), that a second unconfirmed partial response (uPR) was observed in a patient enrolled in its ongoing Phase 1 ACESOT-1051 dose‑escalation study of APR-1051, a WEE1 inhibitor, in patients with advanced solid tumors.

Key Details

• Announcement made by press release filed on Form 8-K on February 18, 2026 (Exhibit 99.1).
• Clinical program: Phase 1 ACESOT-1051 (Multi-Center Evaluation of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors).
• Observed outcome: second unconfirmed partial response (uPR) in a patient during the dose‑escalation portion of the study.
• No financial metrics, corporate leadership changes, or regulatory decisions were reported in this filing.

Why It Matters
A second uPR is an early clinical signal that may indicate APR-1051 has antitumor activity in some patients, which could influence clinical development momentum and investor interest. However, the response is unconfirmed and comes from a Phase 1 dose‑escalation trial primarily designed to assess safety and dosing, so it is not proof of efficacy. Investors should view this as a positive but preliminary clinical update; there were no accompanying financial results or material corporate actions disclosed in the 8-K.